Funding Details
- Awarder
- Inbox
- Date Award
- October 17, 2017
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
-
$42,500,000
Company Info
- Founders
- James McLaughlin
- Company Description
- Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
- Market
- Precision medicine for genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases
- Location
-
Cambridge,
MA,
USA
- Coinvestors
- Atlas Venture, Lightstone Ventures, OrbiMed Advisors
Links